Press Release 2.0The press release today confirms my thoughts from the other day. It is disappointing and is far too late in the game for Rob to be suggesting further additional trials for at home use is a consideration. Essentially, without saying it, something about AcuVid created a significant resistance in the minds of FDA officials. Why they didn't just say a year ago that AcuVid was unlikely to meet approval makes no sense ....because that's definitely my take from the NR.
As for Venowave, Rob gets a pass here because while it's a scientifically proven device ...it's not cheap, and as such there need to be mechanisms in place to supplement costs. It appears these have been addressed and with that substantial sales in 2023. It seems reasonable that investors should expect a stream of positive updates early in the new year.
Benepod is a maybe, the other devices highly unlikely .....to make any significant impact. It would seem now that investors in THRM are investing in Venowave ....with that there is a lot of potential here for significant growth and, as such, for Rob to gain back some investor confidence.